EDP Sciences logo
Subscriber Authentication Point
Sciengine logo
Search
Menu
All issues Volume 21 (2026) Math. Model. Nat. Phenom., 21 (2026) 5 References
Open Access
Issue
Math. Model. Nat. Phenom.
Volume 21, 2026
Article Number 5
Number of page(s) 22
Section Mathematical physiology and medicine
DOI https://doi.org/10.1051/mmnp/2023038
Published online 17 March 2026
  1. H. Sung, J. Ferlay, M. Laversanne, R.L. Siegel, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (2021) 209–249. [Google Scholar]
  2. A. Bhinder, H.V. Jain, S.K. Clinton and A. Friedman, Mathematical modeling of prostate cancer progression in response to androgen ablation therapy. Proc. Natl. Acad. Sci. U.S.A. 108 (2011) 19701–19706. [Google Scholar]
  3. S.E. Eikenberry, J.D. Nagy and Y. Kuang, The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol. Direct 5 (2010) 1–28. [Google Scholar]
  4. A. Friedman and H.V. Jain, A partial differential equation model of metastasized prostatic cancer. Math. Biosci. Eng. 10 (2013) 591–608. [Google Scholar]
  5. H.V. Jain and A. Friedman, Modeling prostate cancer response to continuous versus intermittent androgen ablation therapy. Discrete Continuous Dyn. Syst. B 18 (2013) 945. [Google Scholar]
  6. T. Portz, Y. Kuang and J.D. Nagy, A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy. AIP Adv. 2 (2012) 011002. [Google Scholar]
  7. T.L Jackson, A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. Neoplasia 6 (2004) 697–704. [Google Scholar]
  8. T.L. Jackson, A mathematical model of prostate tumor growth and androgen-independent relapse. Discrete Continuous Dyn, Syst. B 4 (2004) 187. [Google Scholar]
  9. H. Miyamoto, E.M. Messing and C. Chang, Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61 (2004) 332–353. [Google Scholar]
  10. G. Tanaka, Y. Hirata, S.L. Goldenberg, N. Bruchovsky and K. Aihara, Mathematical modelling of prostate cancer growth and its application to hormone therapy. Philos. Trans. Roy. Soc. A Math. Phys. Eng. Sci. 368 (2010) 5029–5044. [Google Scholar]
  11. A.M. Ideta, G. Tanaka, T. Takeuchi and K. Aihara, A mathematical model of intermittent androgen suppression for prostate cancer. J. Nonlinear Sci. 18 (2008) 593–614. [Google Scholar]
  12. N. Sharifi, J.L. Gulley and W.L. Dahut, Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238–244. [Google Scholar]
  13. R. Coletti, A. Pugliese, A. Lunardi, O. Caffo and L. Marchetti, A model-based framework to identify optimal administration protocols for immunotherapies in castration-resistance prostate cancer. Cancers 14 (2022) 135. [Google Scholar]
  14. R. Liu, S. Wang, X. Tan and X. Zou, Identifying optimal adaptive therapeutic schedules for prostate cancer through combining mathematical modeling and dynamic optimization. Appl. Math. Model. 107 (2022) 688–700. [Google Scholar]
  15. P. Colli, H. Gomez, G. Lorenzo, G. Marinoschi, A. Reali and E. Rocca, Mathematical analysis and simulation study of a phase-field model of prostate cancer growth with chemotherapy and antiangiogenic therapy effects. Math. Models Methods Appl. Sci. 30 (2020) 1253–1295. [Google Scholar]
  16. S.S. Salim, E. Mureithi, N. Shaban and J. Malinzi, Mathematical modelling of the dynamics of prostate cancer with a curative vaccine. Sci. Afr. 11 (2021) e00715. [Google Scholar]
  17. R. Coletti, A. Pugliese and L. Marchetti, Modeling the effect of immunotherapies on human castration-resistant prostate cancer. J. Theor. Biol. 509 (2021) 110500. [Google Scholar]
  18. M. Kanikowski, J. Skowronek, M. Kubaszewska, A. Chichel and P. Milecki, Permanent implants in treatment of prostate cancer. Rep. Pract. Oncol. Radiother. 13 (2008) 150–167. [Google Scholar]
  19. M.T. King, M. Keyes, S.J. Frank, J.M. Crook, W.M. Butler and P.J. Rossi, Low dose rate brachytherapy for primary treatment of localized prostate cancer: a systemic review and executive summary of an evidence-based consensus statement. Brachytherapy 20 (2021) 1114–1129. [Google Scholar]
  20. C. Verry, Traitement du cancer localisé de la prostate par curiethérapie à l'iode 125: à propos de 200 patients traites de juillet 2001 à janvier 2011 au chu de grenoble. Thèse de doctorat, 2011. [Google Scholar]
  21. B. Morén, T. Larsson and Å.C. Tedgren, Optimization in treatment planning of high dose-rate Brachytherapy -review and analysis of mathematical models. Med. Phys. 48 (2021) 2057–2082. [Google Scholar]
  22. J. Barnaby and H.V. Jain, Combining androgen deprivation and immunotherapy in prostate cancer treatment: a mechanistic approach. Appl. Sci. 12 (2022) 6954. [Google Scholar]
  23. H.V. Jain, I.C. Sorribes, S.K. Handelman, J. Barnaby and T.L. Jackson, Standing variations modeling captures inter-individual heterogeneity in a deterministic model of prostate cancer response to combination therapy. Cancers 13 (2021) 1872. [Google Scholar]
  24. P.A. Valle, L.N. Coria and K.D. Carballo, Chemoimmunotherapy for the treatment of prostate cancer: insights from mathematical modelling. Appl. Math. Model. 90 (2021) 682–702. [Google Scholar]
  25. L. Blank, M. Bolla and L. Collette, Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an eortc study): a phase iii randomised trial. Lancet 360 (2002) 103–108. [Google Scholar]
  26. A.V. D'Amico, Biochemical outcomes of treatment for prostate cancer - reply. JAMA 284 (2000) 2869–2869. [Google Scholar]
  27. M. Loffredo, A.V. D'Amico and J. Manola, 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821–827. [Google Scholar]
  28. P. Warde, M. Bolla and D. Gonzalez, Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337 (1997) 295–300. [Google Scholar]
  29. R.M Galalae, A. Martinez, T. Mate, C. Mitchell, G. Edmundson, N. Nuernberg, S. Eulau, G. Gustafson, M. Gribble and G. Kovacs, Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (hdr-bt) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 1048–1055. [Google Scholar]
  30. A.R.A. Anderson, A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math. Med. Biol. 22 (2005) 163–186. [CrossRef] [PubMed] [Google Scholar]
  31. M. Fritz, E.A.B.F. Lima, V. Nikolić, J.T. Oden and B. Wohlmuth, Local and nonlocal phase-field models of tumor growth and invasion due to ECM degradation. Math. Models Methods Appl. Sci. 29 (2019) 2433–2468. [Google Scholar]
  32. Y.T. Nguyen Edalgo and A.N. Ford Versypt, Mathematical modeling of metastatic cancer migration through a remodeling extracellular matrix. Processes 6 (2018) 58. [Google Scholar]
  33. A. Toma, A. Mang, T.A. Schuetz, S. Becker and T.M. Buzug, A novel method for simulating the extracellular matrix in models of tumour growth. Computat. Math. Methods Med. 2012 (2012) 109019. [Google Scholar]
  34. H.C. Wong and W.C. Tang, Effects of ECM degradation rate, adhesion, and drag on cell migration in 3D, in 5th Kuala Lumpur International Conference on Biomedical Engineering 2011. Springer (2011) 428–431. [Google Scholar]
  35. R.G Dale, The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br. J. Radiol. 58 (1985) 515–528. [Google Scholar]
  36. H. Mi, C. Petitjean, B. Dubray, P. Vera and S. Ruan, Prediction of lung tumor evolution during radiotherapy in individual patients with pet. IEEE Trans. Med. Imaging 33 (2014) 995–1003. [Google Scholar]
  37. J.Z. Wang, M. Guerrero and X.A. Li, How low is the α/β ratio for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 194–203. [Google Scholar]
  38. A. Friedman, Cancer as multifaceted disease. Math. Model. Natural Phenomena 7 (2012) 3–28. [Google Scholar]
  39. Y. Rikitake and Y. Takai, Chapter three - directional cell migration: regulation by small g proteins, nectin-like molecule-5, and afadin. Int. Rev. Cell Mol. Biol. 287 (2011) 97–143. [Google Scholar]
  40. H. Gustavsson, K. Wekén and J.-E. Damber, Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62 (2005) 364–373. [Google Scholar]
  41. A.S. Lundberg and R.A. Weinberg, Control of the cell cycle and apoptosis1. Eur. J. Cancer 35 (1999) 1886–1894. [Google Scholar]
  42. M. Pavel, M. Renna, S.J. Park, F.M. Menzies, T. Ricketts, J. Füllgrabe, A. Ashkenazi, R.A. Frake, A.C. Lombarte, C.F. Bento, et al., Contact inhibition controls cell survival and proliferation via yap/taz-autophagy axis. Nat. Commun. 9 (2018) 1–18. [Google Scholar]
  43. M. Adhyam and A.K. Gupta, A review on the clinical utility of PSA in cancer prostate. Indian J. Surg. Oncol. 3 (2012) 120–129. [Google Scholar]
  44. B. Jones, R.G. Dale, C. Bleasdale, L.T. Tan and M. Davies, A mathematical model of intraluminal and intracavitary brachytherapy. Br. J. Radiol. 67 (1994) 805–812. [Google Scholar]
  45. F.H. Attix, Introduction to Radiological Physics and Radiation Dosimetry. John Wiley & Sons (2008). [Google Scholar]
  46. E.B. Podgorsak, Basic radiation physics. Radiation Oncology Physics: A Handbook for Teachers and Students. IAEA, Vienna (2005) 7. [Google Scholar]
  47. A.J. Giaccia and E.J. Hall, Radiobiology for the Radiologist, 7th edn. Wolters Kluwer Health/Lippincott Williams & Wilkins (2012). [Google Scholar]
  48. V.Y. Kuperman, Effect of heterogeneous radiosensitivity on the optimal fractionation in radiotherapy. Phys. Med. 67 (2019) 185–191. [Google Scholar]
  49. L. Sieminska, M. Ferguson, T.W. Zerda and E. Couch, Diffusion of steroids in porous sol-gel glass: application in slow drug delivery. J. Sol-Gel Sci. Technol. 8 (1997) 1105–1109. [Google Scholar]
  50. K.R Swanson, L.D True, D.W Lin, K.R Buhler, R. Vessella and J.D Murray, A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly. Am. J. Pathol. 158 (2001) 2195–2199. [Google Scholar]
  51. R.R Berges, J. Vukanovic, J.I. Epstein, M. CarMichel, L. Cisek, D.E Johnson, R.W. Veltri, P.C. Walsh and J.T. Isaacs, Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1 (1995) 473–480. [Google Scholar]
  52. D. Sybelle, Développement d'une méthode de caractérisation spectrale des faisceaux de photons d'énergies inférieures à 150 keV utilisés en dosimétrie. PhD thesis, Universite Paris Sud-Paris XI, 2014. [Google Scholar]
  53. F. Hecht, New development in freefem++. J. Numer. Math. 20 (2012) 251–266. [CrossRef] [MathSciNet] [Google Scholar]
  54. F. Hecht, O. Pironneau, A. Le Hyaric and K. Ohtsuka, Freefem++ manual, 2005. [Google Scholar]
  55. D.F. Moore, G.L. u Yao, P.C. Albertsen, Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 81 (2008) 300–173. [Google Scholar]
  56. I. Tannock, H.I. Scher and S. Halabi, Prostate cancer clinical trials working group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J. Clin. Oncol. 26 (2008) 1148–1159. [Google Scholar]
  57. I.F. Tannock and B. Seruga, Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat. Clin. Pract. Oncol. 5 (2008) 574–576. [Google Scholar]
  58. C.S. Higano, W. Ellis and P.H. Lange, Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48 (1996) 800–804. [Google Scholar]
  59. C.S. Higano, A. Shields, N. Wood, J. Brown and C. Tangen, Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64 (2004) 1182–1186. [Google Scholar]
  60. J.L. Wright, C.S. Higano and D.W. Lin, Intermittent androgen deprivation: clinical experience and practical applications. Urol. Clin. North Am. 33 (2006) 167–179. [Google Scholar]
  61. D. Bostwick, P. Grimm and I. Billiet, Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group. BJU Int. 1 (2012) 22–29. [Google Scholar]
  62. D.J. Demanes, Y. Yamada and L. Rogers, American brachytherapy society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11 (2012) 20–32. [Google Scholar]
  63. P.M. Devlin, M.J. Rivard and W.M. Butler, American brachytherapy society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 6 (2007) 34–37. [Google Scholar]
  64. G. Kovacs, R. Pötter, T. Loch, J. Hammer, I.-K. Kolkman-Deurloo, J.J.M.C.H. de la Rosette and H. Bertermann, Gec/estro-eau recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol. 74 (2005) 137–148. [Google Scholar]
  65. W.R. Lee, B.J. Davis and E.M. Horwitz, American brachytherapy society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11 (2012) 6–19. [Google Scholar]
  66. Y. Otani, Y. Yoshioka and O. Suzuki, High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective. J. Contemp. Brachyther. 6 (2014) 91–98. [Google Scholar]
  67. J. Skowronek, Current status of brachytherapy in cancer treatment - short overview. J. Contemp. Brachyther. 9 (2017) 581–589. [Google Scholar]
  68. D. Mengmeng, Z. Xueliang and J. Dechao, Brachytherapy combined with or without hormone therapy for localized prostate cancer: a meta-analysis and systematic review. Front. Oncol. 10 (2020) 169. [Google Scholar]
  69. N.N. Stone, L.N. Lee and R.G. Stock, Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 52 (2002) 444–452. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.